Item 8.01 Other Events.
On February 3, 2022, SOC Telemed, Inc. ("Company") issued a press release
announcing the execution of an Agreement and Plan of Merger (the "Merger
Agreement"), dated as of February 2, 2022, by and among the Company, Spark
Parent, Inc., a Delaware corporation ("Parent"), and Spark Merger Sub, Inc., a
Delaware corporation and direct, wholly owned subsidiary of Parent ("Merger
Sub"), pursuant to which Merger Sub will merge with and into the Company (the
"Merger"), with the Company surviving the Merger as a direct, wholly owned
subsidiary of Parent. Parent and Merger Sub are affiliates of funds advised by
Patient Square Capital. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated by reference herein.
Important Information and Where to Find It
In connection with the proposed transaction between the Company and Patient
Square Capital, the Company will file with the Securities and Exchange
Commission ("SEC") relevant materials, including a proxy statement (the "Proxy
Statement"), the definitive version of which will be sent or provided to the
Company's stockholders. The Company may also file other documents with the SEC
regarding the proposed transaction. This communication is not a substitute for
the Proxy Statement or any other document which the Company may file with the
SEC or send to its stockholders in connection with the proposed transaction.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY
OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL
AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR
ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
PROPOSED TRANSACTION, PARTIES TO THE PROPOSED TRANSACTION AND RELATED MATTERS.
Investors and security holders may obtain free copies of the Proxy Statement
(when it is available) and other documents that are filed or will be filed with
the SEC by the Company through the website maintained by the SEC at www.sec.gov,
the Company's investor relations website at https://investors.soctelemed.com or
by contacting the Company's investor relations department at the following:
SOC Telemed, Inc.
srubis@soctelemed.com
(214) 681-7991
Participants in the Solicitation
The Company and certain of its directors and executive officers may be deemed to
be participants in the solicitation of proxies in respect of the proposed
transaction. Information regarding the Company's directors and executive
officers, including a description of their direct interests, by security
holdings or otherwise, is contained in the Company's proxy statement for its
2021 annual meeting of stockholders, which was filed with the SEC on May 10,
2021. Additional information regarding the direct and indirect interests of the
participants in the solicitation of proxies in connection with the proposed
transaction, including the interests of the Company's directors and executive
officers in the transaction, which may be different than those of the Company's
stockholders generally, will be included in the Proxy Statement that will be
filed with the SEC relating to the proposed transaction when it becomes
available. You may obtain free copies of these documents, when available, using
the sources indicated above.
1
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of
the federal securities laws, including Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are based on the Company's current
expectations, estimates and projections about the expected date of closing of
the proposed transaction and the potential benefits thereof, its business and
industry, management's beliefs and certain assumptions made by the Company and
Patient Square Capital, all of which are subject to change. In this context,
forward-looking statements often address expected future business and financial
performance and financial condition, and often contain words such as "expect,"
"anticipate," "intend," "plan," "believe," "could," "seek," "see," "will,"
"may," "would," "might," "potentially," "estimate," "continue," "expect,"
"target," similar expressions or the negatives of these words or other
comparable terminology that convey uncertainty of future events or outcomes. All
forward-looking statements by their nature address matters that involve risks
and uncertainties, many of which are beyond our control, and are not guarantees
of future results, such as statements about the consummation of the proposed
transaction and the anticipated benefits thereof. These and other
forward-looking statements, including statements about the parties' ability to
consummate the proposed transaction on the anticipated timeframe or at all, to
make any filing or take any other action required to consummate the proposed
transaction on the anticipated timeframe or at all, or to realize the
anticipated benefits of the proposed transaction, are not guarantees of future
results and are subject to risks, uncertainties and assumptions that could cause
actual results to differ materially from those expressed in forward-looking
statements. Accordingly, there are or will be important factors that could cause
actual results to differ materially from those indicated in such statements and,
therefore, you should not place undue reliance on any such statements and
caution must be exercised in relying on forward-looking statements. Important
risk factors that may cause such a difference include, but are not limited to:
(i) the completion of the proposed transaction on the anticipated terms and
timeframe, including obtaining stockholder and regulatory approvals, anticipated
tax treatment, unforeseen liabilities, future capital expenditures, revenues,
expenses, earnings, synergies, economic performance, indebtedness, financial
condition, losses, future prospects, business and management strategies for the
management, expansion and growth of the Company's business and other conditions
to the completion of the proposed transaction; (ii) the impact of the COVID-19
pandemic on the Company's business and general economic conditions; (iii) the
Company's ability to implement its business strategy; (iv) significant
transaction costs associated with the proposed transaction; (v) potential
litigation relating to the proposed transaction; (vi) the risk that disruptions
from the proposed transaction will harm the Company's business, including
current plans and operations; (vii) the ability of the Company to retain and
hire key personnel; (viii) potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the proposed
transaction; (ix) legislative, regulatory and economic developments affecting
the Company's business; (x) general economic and market developments and
conditions; (xi) the evolving legal, regulatory and tax regimes under which the
Company operates; (xii) potential business uncertainty, including changes to
existing business relationships, during the pendency of the proposed transaction
that could affect the Company's financial performance; (xiii) restrictions
during the pendency of the proposed transaction that may impact the Company's
ability to pursue certain business opportunities or strategic transactions;
(xiv) unpredictability and severity of catastrophic events, including, but not
limited to, acts of terrorism, outbreak of war or hostilities or pandemics; (xv)
any potential negative effects of this communication or the consummation of the
proposed transaction on the market price of SOC Telemed's common stock; and
(xvi) other factors as set forth from time to time in the Company's filings with
the SEC, including its Annual Report on Form 10-K for the year ended December
31, 2020, and its Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2021, each as may be updated or supplemented by any subsequent
filings that the Company may file with the SEC, as well as the Company's
response to any of the aforementioned factors. These risks, as well as other
risks associated with the proposed transaction, will be more fully discussed in
the Proxy Statement to be filed with the SEC in connection with the proposed
transaction. Investors are cautioned not to place undue reliance on such
statements which speak only as of the date they are made. While the list of
factors presented here is, and the list of factors presented in the Proxy
Statement will be, considered representative, no such list should be considered
to be a complete statement of all potential risks and uncertainties. Unlisted
factors may present significant additional obstacles to the realization of
forward-looking statements. Consequences of material differences in results as
compared with those anticipated in the forward-looking statements could include,
among other things, business disruption, operational problems, financial loss,
legal liability to third parties and other similar risks, any of which could
have a material adverse effect on the Company's financial condition, results of
operations, or liquidity. The Company does not assume any obligation to publicly
provide revisions or updates to any forward-looking statements, whether as a
result of new information, future developments or otherwise, should
circumstances change, except as otherwise required by securities and other
applicable laws.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated February 3, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
© Edgar Online, source Glimpses